Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Recruiting now Phase 2 NCT06463743
Run by State University of New York at Buffalo · for 55 to 75 · All sexes
What this study is about
The goal of the study is to learn about treating older people with multiple sclerosis (MS) with metformin. Metformin may be used as a single therapy or as an add-on therapy. The investigators want to learn: * The safety and tolerability of metformin extended release (1500 mg/day) as a single therapy or as an add-on therapy in older people with MS compared to placebo * How well metformin protects the nervous system against injury compared with placebo measured by brain MRI over a 9 month treatment period * The effect of metformin to protect brain tissue from age and MS related injury when compared to the placebo group over a 9 month treatment period
Who can join (things the study team will check)
✅ You may be able to join if…
- age between 55 and 75 years old
- having a diagnosis of MS based on the latest McDonald criteria
- non-active disease course (no relapses and no MRI activity) in the last 2 years as determined by the MS provider and based on the 2020 revised clinical course criteria
- EDSS score <7.0
🚫 You may not be able to join if…
- inability to undergo MRI scans
- inability to participate in the study during the study period
- diabetes or uncontrolled cardiovascular disease
- unable to consent
Where this trial is running
- UBMD Neurolgy, Buffalo, New York, United States
Who to contact
Kara Patrick · 7168295037 · kpatrick@buffalo.edu
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06463743.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.